A ceramic-based anticancer drug delivery system to treat breast cancer.
Drug delivery systems offer the advantage of sustained targeted release with minimal side effect. In the present study, the therapeutic efficacy of a porous silica-calcium phosphate nanocomposite (SCPC) as a new delivery system for 5-Fluorouracil (5-FU) was evaluated in vitro and in vivo. In vitro studies showed that two formulations; SCPC50/5-FU and SCPC75/5-FU hybrids were very cytotoxic for 4T1 mammary tumor cells. In contrast, control SCPCs without drug did not show any measurable toxic effect. Release kinetics studies showed that SCPC75/5-FU hybrid provided a burst release of 5-FU in the first 24 h followed by a sustained release of a therapeutic dose (30.7 microg/day) of the drug for up to 32 days. Moreover, subcutaneous implantation of SCPC75/5-FU hybrid disk in an immunocompetent murine model of breast cancer stopped 4T1 tumor growth. Blood analyses showed comparable concentrations of Ca, P and Si in animals implanted with or without SCPC75 disks. These results strongly suggest that SCPC/5-FU hybrids can provide an effective treatment for solid tumors with minimal side effects.
El-Ghannam
Ahmed
A
Department of Mechanical Engineering and Engineering Science, DCH 177, The University of North Carolina at Charlotte, 9201 University City Blvd., Charlotte, NC 28223, USA. arelgha@uncc.edu
Ricci
Krista
K
Malkawi
Ahmed
A
Jahed
Kiarash
K
Vedantham
Kumar
K
Wyan
Heather
H
Allen
Lauren D
LD
Dréau
Didier
D
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002516:Ceramics; D005260:Female; D006801:Humans
D000970:Antineoplastic Agents